. 2024 Sep 2;156(2):280–292. doi: 10.1002/ijc.35154

TABLE 2.

MHT use prior to diagnosis and ovarian cancer‐specific survival among peri‐/postmenopausal women (n = 690).

			All (n = 690)		HGSC (n = 525)		Non‐HGSC (n = 165)
Variable ^a	Total ^b (n, %)	Deaths (n, %)	HR	95%CI	HR	95%CI	HR	95%CI
MHT use
Never	417 (60)	224 (62)	1.0		1.0		1.0
Ever	273 (40)	137 (38)	0.74	0.60–0.92	0.69	0.54–0.87	1.34	0.71–2.54
Recency of use
Former	178 (26)	94 (26)	0.74	0.57–0.95	0.67	0.51–0.88	1.40	0.69–2.84
Current/recent	94 (14)	43 (12)	0.76	0.55–1.04	0.73	0.52–1.02	1.23	0.47–3.23
MHT type
ET	87 (15)	39 (13)	0.84	0.59–1.21	0.90	0.61–1.33	1.01	0.37–2.75
E‐P/P	82 (14)	41 (14)	0.67	0.48–0.93	0.62	0.44–0.88	1.64	0.56–4.78
MHT duration ^c
<5 years	128 (19)	60 (17)	0.70	0.53–0.93	0.63	0.46–0.86	1.30	0.60–2.78
5+ years	137 (20)	72 (20)	0.77	0.59–1.01	0.72	0.55–0.96	1.35	0.55–3.35

Abbreviations: CI, confidence interval; E‐P/P, oestrogen plus progestin or progestogen‐only therapy; ET, oestrogen‐alone hormone therapy; HGSC, high‐grade serous carcinoma; HR, hazard ratio; MHT, menopausal hormone therapy.

^{^a}

All models adjusted for age (<55, 55–59, 60–64, 65–69, 70+), body mass index (<25, 25–29, 30+ kg/m²) smoking (never, former, current), history of hysterectomy prior to diagnosis (yes, no) and stratified by FIGO Stage (I & II, III & IV). Further adjustment for any other variables did not make any difference.

^{^b}

The counts in sub‐categories may not add up to the total number due to missing data.

^{^c}

Mean (standard deviation) duration of MHT: <5 years = 20 months (15.3); 5+ years = 12 years (6.9).